MediWound Ltd. Stock News

Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022

Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022

Equities research analysts expect that MediWound Ltd. (NASDAQ:MDWD) will announce sales of $5.65 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for MediWounds earnings, with estimates ranging from $5.60 million to $5.70 million. MediWound reported sales of $6.67 million in the same quarter last year, which would indicate a []

MediWound Ltd. (NASDAQ:MDWD) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 323,800 shares, a drop of 20.7% from the October 31st total of 408,500 shares. Based on an average daily volume of 100,300 shares, the short-interest ratio is currently []

Squarepoint Ops LLC acquired a new stake in MediWound Ltd. (NASDAQ:MDWD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 17,009 shares of the biopharmaceutical companys stock, valued at approximately $65,000. Squarepoint Ops LLC owned approximately 0.06% of MediWound as of []

MediWound Ltd. (NASDAQ:MDWD) Equities research analysts at Oppenheimer cut their FY2021 earnings per share (EPS) estimates for MediWound in a research note issued on Tuesday, November 16th. Oppenheimer analyst K. Degeeter now expects that the biopharmaceutical company will earn ($0.48) per share for the year, down from their previous estimate of ($0.46). Oppenheimer also []

Anticipate Submission for Label Extension in First Half 2022 Anticipate Submission for Label Extension in First Half 2022

MediWound (NASDAQ:MDWD) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters consensus estimate of ($0.13) by $0.01, MarketWatch Earnings reports. MediWound had a negative return on equity of 171.14% and a negative net margin of 38.43%. During the same quarter last []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis Treatment Candidate Keza

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.